| |

Adjuvant Radiotherapy May Not Lengthen Mesothelioma Survival, Study Shows

ByAlex Strauss

adjuvant radiotherapyHaving adjuvant radiotherapy after surgery may not help mesothelioma patients live any longer according to researchers at Duke and Stanford Universities.

Researchers used a database of pleural mesothelioma patients from Duke and a national registry to conduct the analysis. 

They compared the outcomes of patients who had radiation after surgery (adjuvant radiotherapy) with the outcomes of those who did not. 

While radiotherapy may help reduce mesothelioma symptoms for some patients, the results of the study suggest that it is unlikely to extend survival.

Radiation for Mesothelioma and Its Symptoms

Radiotherapy is a mainstay of cancer therapy for certain kinds of cancer. But the irregular shape and aggressive nature of mesothelioma tumors makes them less than ideal for radiation treatment. 

Pleural mesothelioma patients who are healthy enough tend to get the best results from surgery. During mesothelioma surgery, doctors remove the diseased pleural membrane. They may also remove other at-risk tissues, including one of the lungs. 

When mesothelioma patients do have radiation, it is usually in the form of adjuvant radiotherapy. This is radiation that is delivered after surgery. The goal of adjuvant radiotherapy is to kill any cells left behind after the operation. If they are not destroyed, these cells could give rise to new mesothelioma tumors. 

Targeted radiation may also help slow the growth of existing mesothelioma tumors. Doctors sometimes use it to reduce symptoms like the buildup of lung fluid.

Mesothelioma Survival With and Without Adjuvant Radiotherapy 

The new study included patients with Stage I, II, or III pleural mesothelioma. There were 212 patients who had surgery at Duke University between 1996 and 2016. Researchers also included 1,615 mesothelioma patients from the National Cancer Database. These patients had surgery between 2004 and 2015. 

The patients chosen to receive adjuvant radiotherapy usually had no signs of cancer around the edges where the tumor was removed. They also tended to be patients with more advanced mesothelioma.

“At a landmark time of 4.4 and 4.7 months from surgery, Duke and NCDB patients who received adjuvant radiation did not experience improved survival compared to those who did not receive radiation in multivariable analysis,” writes Dr. Vignesh Raman, a Duke thoracic surgeon who was lead author on the paper.

Duke patients who had adjuvant radiotherapy had similar recurrence rates as those who had none. It also took about the same amount of time for their cancer to start growing again or to occur on the other side of their chest. About half of them had mild side effects. But more than one in five had serious complications from radiation.

The report concludes that adjuvant radiotherapy does not improve the odds of surviving mesothelioma. 

Malignant mesothelioma is an asbestos-linked cancer with few viable treatment options. About 2,500 Americans receive a mesothelioma diagnosis every year. 

Source:

Raman, V, et al, “The Impact of Adjuvant Hemithoracic Radiation on Outcomes in Patients with Stage I-III Malignant Pleural Mesothelioma: A Dual Registry Analysis”, June 4, 2021, Annals of Surgery, Online ahead of print, https://journals.lww.com/annalsofsurgery/Abstract/9000/The_Impact_of_Adjuvant_Hemithoracic_Radiation_on.93523.aspx

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…